Booth #91J29
AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, recently acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, will attend CPHI 22, Frankfurt to discuss the significant opportunities open to European biotechs conducting their clinical research in Australia.
Book a meeting with us at CPHI via Connect to Frankfurt partnering or via our website.
AcuraBio brings two decades of experience in innovative therapeutics for customers in the biotech, pharmaceutical, and animal health industries. The CDMO provides recombinant proteins, vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics.
Dr. Tim Evans, AcuraBio’s Head of Science & Technology will share how Australia offers clinical-stage biotechs the world’s most attractive financial and regulatory incentives.
These include:
- A rebate of almost 50% on clinical spend including CDMO services
- No IND requirement
- Approval processes that can take only 4-5 weeks
The company has recently appointed international biopharma executive Guillaume Herry as CEO. Mr. Herry brings over 15 years of international operational and strategic growth experience across the biopharmaceutical and medical device industries in the US, Europe, and Australia.
Mr. Herry said: “I’m excited to be part of this new phase of growth and to be working with Glenn and the Ampersand team. I look forward to leveraging the business’ deep technical experience to grow the company and expand the service offering.”
“Our scientific expertise is key to our biotech clients’ clinical success, so we are pleased to have Dr. Tim Evans attend CPHI to share with the biotech community the scientific benefits AcuraBio, and Australia, offers their clinical research programs.”
Book a meeting with us at CPHI via Connect to Frankfurt partnering or via our website.
About AcuraBio
AcuraBio Pty Ltd is one of Australia’s most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials. Additional information about AcuraBio is available at www.acurabio.com.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience in seeking to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com
